Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright reaffirmed its Buy rating and $80 price target on Beam Therapeutics Inc. (NASDAQ:BEAM). The rating follows Beam’s fourth-quarter and full-year 2025 results, which showed considerable progress in the company’s product pipeline.

The company announced BEAM-304, an innovative gene editing program for phenylketonuria, with an experimental new medication filing expected in 2026. Meanwhile, new data from BEAM-302 in alpha-1 antitrypsin deficiency continues on schedule for the first quarter of 2026, including information on an FDA-guided prospective accelerated pivotal path.

Beam Therapeutics Inc. (NASDAQ:BEAM) also revealed a $500 million senior secured, long-term non-dilutive contract with Sixth Street, which will serve as support for the possible commercial launch of Risto-Cel. The company reported $1.25 billion in cash, cash equivalents, and marketable securities at the end of 2025. With the expected minimum $200 million pull from Sixth Street, the company forecasts a financial runway through mid-2029.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

While we acknowledge the risk and potential of BEAM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.